CYP19A1 and breast cancer: Optimal adjuvant therapy for early hormone sensitive breast cancer patients includes estrogen deprivation, either by blocking estrogen receptors at the target tissues using selective estrogen receptor modulators (SERMs), e.g., tamoxifen, or by decreasing estrogen production through inhibition of aromatase activity using AIs.